Jacob M Rowe

List of Publications by Year
in descending order

278	18,576	28736 57	14779 131
papers	citations	h-index	g-index

304	304	304	16735
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Consolidation in AML: Abundant opinion and much unknown. Blood Reviews, 2022, 51, 100873.	2.8	5
2	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 2022, 6, 828-847.	2.5	5
3	Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRN. Journal of Crohn's and Colitis, 2022, 16, 786-795.	0.6	13
4	Toward further excellence in <i>Haematologica</i>. Haematologica, 2022, 107, 2-2.	1.7	1
5	The â€œ7+3â€•regimen in acute myeloid leukemia. Haematologica, 2022, 107, 3-3.	1.7	14
6	The predictive value of a positive phase II ASH abstract for peer-reviewed publication and progression to phase III. Blood, 2022, , .	0.6	1
7	Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment. Experimental Hematology, 2022, 107, 20-23.	0.2	10
8	Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood, 2022, 139, 3519-3531.	0.6	20
9	Cytogenetics or MRD in B-cell ALL. Do both reign supreme?. Leukemia, 2022, 36, 1201-1202.	3.3	0
10	Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nature Cancer, 2022, 3, 768-782.	5.7	15
11	BLâ€8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An openâ€label safety and efficacy phase 2a study. Cancer, 2021, 127, 1246-1259.	2.0	21
12	Perspectives on current survival and new developments in AML. Best Practice and Research in Clinical Haematology, 2021, 34, 101248.	0.7	15
13	Molecular classification improves risk assessment in adult BCR-ABL1â€“negative B-ALL. Blood, 2021, 138, 948-958.	0.6	59
14	Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.. Journal of Clinical Oncology, 2021, 39, 7007-7007.	0.8	1
15	Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 41-54.	1.2	8
16	Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. British Journal of Haematology, 2021, 194, 309-318.	1.2	10
17	Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discovery, 2021, 11, 2846-2867.	7.7	83
18	Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia. Engineering, 2021, 7, 1354-1368.	3.2	0

#	Article	IF	Citations
19	CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. Blood Advances, 2021, 5, 4560-4568.	2.5	12
20	Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia. Biologics: Targets and Therapy, 2021, Volume 15, 419-431.	3.0	1
21	Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Leukemia Research, 2021, 111, 106736.	0.4	3
22	Changing trends in the therapy of acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101333.	0.7	3
23	Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study. Blood, 2021, 138, 413-413.	0.6	1
24	Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials. Blood, 2021, 138, 690-690.	0.6	0
25	Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of "Positive" Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 - 2015. Blood, 2021, 138, 4040-4040.	0.6	0
26	Newly diagnosed myeloma patients with low-burden disease may benefit from tandem autologous stem cell transplantation: results of long-term follow-up. Bone Marrow Transplantation, 2020, 55, 1200-1202.	1.3	0
27	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
28	Bone marrow blast elimination by the fifth day of 7â€‰+â€‰3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61â€‰years of age: A longâ€term followâ€up of a multiâ€center prospective study. American Journal of Hematology, 2020, 95, E3-E5.	2.0	0
29	Pharmacological prophylaxis of infection in pediatric acute myeloid leukemia patients. Expert Opinion on Pharmacotherapy, 2020, 21, 193-205.	0.9	8
30	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 1113-1127.	5.7	32
31	Venetoclax is safe and efficacious in relapsed/refractory AML. Leukemia and Lymphoma, 2020, 61, 2221-2225.	0.6	30
32	At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. British Journal of Haematology, 2020, 191, 37-43.	1.2	9
33	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	2.5	63
34	A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 2191-2199.	0.6	4
35	How we treat older patients with acute myeloid leukaemia. British Journal of Haematology, 2020, 191, 682-691.	1.2	3
36	Forward into the second century of Haematologica. Haematologica, 2020, 105, 2498.	1.7	0

#	Article	IF	Citations
37	Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation. Blood, 2020, 136, 9-10.	0.6	0
38	Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study. Blood, 2020, 136, 24-25.	0.6	1
39	Advances in BCR/ABL positive ALL. Advances in Cell and Gene Therapy, 2019, 2, e60.	0.6	0
40	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123.	2.0	77
41	Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematology,the, 2019, 6, e122-e131.	2.2	20
42	The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). Leukemia Research, 2019, 78, 29-33.	0.4	2
43	Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis. Leukemia Research, 2019, 82, 36-42.	0.4	22
44	Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation. Leukemia and Lymphoma, 2019, 60, 2449-2456.	0.6	14
45	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Advances, 2019, 3, 670-680.	2.5	71
46	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836.	2.5	89
47	BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. Blood Advances, 2019, 3, 3740-3749.	2.5	10
48	Will new agents impact survival in AML?. Best Practice and Research in Clinical Haematology, 2019, 32, 101094.	0.7	21
49	Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. Haematologica, 2019, 104, e147-e150.	1.7	4
50	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	9.4	384
51	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. American Journal of Hematology, 2019, 94, 111-117.	2.0	21
52	Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML. Blood, 2019, 134, 5091-5091.	0.6	1
53	A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DARTÂ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2019, 134, 2662-2662.	0.6	11
54	Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML). Blood, 2019, 134, 1309-1309.	0.6	9

#	Article	IF	Citations
55	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. Blood, 2019, 134, 115-115.	0.6	19
56	Primary plasma cell leukemia in the era of novel agents for myeloma â€“ a multicenter retrospective analysis of outcome. Leukemia Research, 2018, 68, 9-14.	0.4	14
57	Revisiting autologous transplantation in acute myeloid leukemia. Current Opinion in Hematology, 2018, 25, 95-102.	1.2	12
58	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 945-955.	2.0	7
59	Progress and predictions: AML in 2018. Best Practice and Research in Clinical Haematology, 2018, 31, 337-340.	0.7	16
60	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances, 2018, 2, 2922-2936.	2.5	35
61	Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia. Haematologica, 2018, 103, e489-e490.	1.7	26
62	Advances in the genetics of acute lymphoblastic leukemia in adults and the potential clinical implications. Expert Review of Hematology, 2018, 11, 781-791.	1.0	11
63	Very poor longâ€term survival in past and more recent studies for relapsed AML patients: The ECOGâ€ACRIN experience. American Journal of Hematology, 2018, 93, 1074-1081.	2.0	93
64	Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse. Blood, 2018, 132, 5206-5206.	0.6	6
65	Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age â‰¥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial. Blood, 2018, 132, 437-437.	0.6	4
66	Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation. Blood, 2018, 132, 3379-3379.	0.6	1
67	FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age â‰¥60 Years. Blood, 2018, 132, 3995-3995.	0.6	3
68	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	0.6	14
69	The Predictive Value of Thromboelastogram in the Evaluation of Patients with Suspected Acute Venous Thromboembolism. Blood, 2018, 132, 5052-5052.	0.6	1
70	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 767-775.	2.0	41
71	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood, 2017, 129, 1763-1767.	0.6	78
72	Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia. Expert Opinion on Orphan Drugs, 2017, 5, 369-374.	0.5	2

#	Article	IF	Citations
73	High Frequency and Poor Outcome of Philadelphia Chromosomeâ€“Like Acute Lymphoblastic Leukemia in Adults. Journal of Clinical Oncology, 2017, 35, 394-401.	0.8	326
74	Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia. Current Treatment Options in Oncology, 2017, 18, 20.	1.3	8
75	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. Leukemia Research, 2017, 59, 55-64.	0.4	17
76	Published abstracts at international meetings often over- or underestimate the initial response rate. Blood, 2017, 129, 2326-2328.	0.6	7
77	AML in 2017: Advances in clinical practice. Best Practice and Research in Clinical Haematology, 2017, 30, 283-286.	0.7	13
78	Which patients should I transplant with acute lymphoblastic leukemia?. Best Practice and Research in Clinical Haematology, 2017, 30, 249-260.	0.7	10
79	Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. Expert Opinion on Biological Therapy, 2017, 17, 1557-1564.	1.4	10
80	BST-236. Journal of Clinical Oncology, 2017, 35, e18520-e18520.	0.8	0
81	A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOGâ€ACRIN cancer research group (E1908). American Journal of Hematology, 2016, 91, 308-312.	2.0	13
82	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	2.0	45
83	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica, 2016, 101, 1524-1533.	1.7	154
84	Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults. Current Oncology Reports, 2016, 18, 39.	1.8	38
85	Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood, 2016, 127, 1551-1558.	0.6	105
86	How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood, 2016, 128, 488-496.	0.6	45
87	Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. Journal of Clinical Oncology, 2016, 34, 3544-3553.	0.8	99
88	Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. American Journal of Hematology, 2016, 91, 1107-1112.	2.0	7
89	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications, 2016, 7, 13331.	5.8	218
90	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine, 2016, 22, 1488-1495.	15.2	195

#	Article	IF	Citations
91	AML in 2016: Where we are now?. Best Practice and Research in Clinical Haematology, 2016, 29, 315-319.	0.7	11
92	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016, 48, 1481-1489.	9.4	231
93	Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations forÂNew Diagnostic Criteria. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 146-151.	0.2	22
94	Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience. Biology of Blood and Marrow Transplantation, 2016, 22, 1043-1048.	2.0	11
95	Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy. Biology of Blood and Marrow Transplantation, 2016, 22, 975-981.	2.0	29
96	The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. Blood, 2016, 128, 2745-2745.	0.6	3
97	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age â‰¥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. Blood, 2016, 128, 339-339.	0.6	7
98	Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series. Blood, 2016, 128, 5699-5699.	0.6	1
99	Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study. Blood, 2016, 128, 1650-1650.	0.6	0
100	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	0.6	110
101	Severe and persistent heparinâ€induced thrombocytopenia despite fondaparinux treatment. American Journal of Hematology, 2015, 90, 675-678.	2.0	59
102	Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy. British Journal of Haematology, 2015, 170, 50-55.	1.2	26
103	Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the â€œ3â€‰+â€‰7â€•induction regimen for acute myeloid leukemia. American Journal of Hematology, 2015, 90, 1159-1164.	2.0	22
104	Impact of Pretransplantation 18F-fluorodeoxy Glucoseâ€“Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, 1605-1611.	2.0	39
105	Introducing minimal residual disease in acute myeloid leukemia. Current Opinion in Hematology, 2015, 22, 139-145.	1.2	10
106	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 28, 343-356.	7.7	145
107	Reasons for optimism in the therapy of acute leukemia. Best Practice and Research in Clinical Haematology, 2015, 28, 69-72.	0.7	9
108	Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902. Blood, 2015, 126, 1308-1308.	0.6	7

#	Article	IF	Citations
109	North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age â‰¥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906). Blood, 2015, 126, 217-217.	0.6	28
110	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. Blood, 2015, 126, 2546-2546.	0.6	15
111	High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. Blood, 2015, 126, 2618-2618.	0.6	5
112	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. Blood, 2015, 126, 693-693.	0.6	1
113	Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL. Blood, 2015, 126, 1422-1422.	0.6	0
114	Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience. Blood, 2015, 126, 1315-1315.	0.6	0
115	The increasing genomic complexity of acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2014, 27, 209-213.	0.7	8
116	Transplantation in Acute Myeloid Leukemia. Hematology/Oncology Clinics of North America, 2014, 28, 983-994.	0.9	9
117	Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis. Experimental Hematology, 2014, 42, 457-463.	0.2	22
118	Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature, 2014, 514, 513-517.	13.7	340
119	Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 1021-1025.	2.0	61
120	Allotransplantation for Patients Age â‰¥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 960-968.	2.0	37
121	Younger adults with acute myeloid leukemia in remission for â‰¥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. Leukemia Research, 2014, 38, 901-906.	0.4	10
122	Pathogenesis and prognostication in acute lymphoblastic leukemia. F1000prime Reports, 2014, 6, 59.	5.9	21
123	UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood, 2014, 123, 843-850.	0.6	321
124	Histamine dihydrochloride for maintaining remission in acute myeloid leukemia. International Journal of Hematologic Oncology, 2014, 3, 137-143.	0.7	0
125	Minimal Residual Disease Assessment By Flow Cytometry in AML Is an Independant Prognostic Factor Even after Adjusting for Cytogenetic/Molecular Abnormalities. Blood, 2014, 124, 1016-1016.	0.6	7
126	Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML. Blood, 2014, 124, 2599-2599.	0.6	10

#	Article	IF	Citations
127	High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900. Blood, 2014, 124, 373-373.	0.6	7
128	A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906. Blood, 2014, 124, 3742-3742.	0.6	5
129	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. Blood, 2014, 124, 950-950.	0.6	11
130	Prevalence and Incidence of Acute Myeloid Leukemia May be Higher Than Currently Accepted Estimates Among the â‰¥65 Year-Old Population in the United States. Blood, 2014, 124, 958-958.	0.6	9
131	Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia. Blood, 2014, 124, 2375-2375.	0.6	0
132	Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation Is Safe and Effective: 1 Year Follow-up. Blood, 2014, 124, 5866-5866.	0.6	0
133	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood, 2014, 124, 132-132.	0.6	1
134	Semaphorin 3A Expression on Donor and Recipient Regulatory Cells: A Novel Pre-Transplant Biomarker Predicting the Development of Acute Graft-Versus-Host Disease. Blood, 2014, 124, 3935-3935.	0.6	0
135	Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT). Blood, 2014, 124, 208-208.	0.6	1
136	Secondary ALL May be Independent of Prior Cytotoxic Therapy. Blood, 2014, 124, 3648-3648.	0.6	0
137	Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era. Blood, 2014, 124, 948-948.	0.6	1
138	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell, 2013, 24, 766-776.	7.7	220
139	Important milestones in acute leukemia in 2013. Best Practice and Research in Clinical Haematology, 2013, 26, 241-244.	0.7	14
140	High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2013, 31, 676-683.	0.8	171
141	Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leukemia Research, 2013, 37, 32-36.	0.4	29
142	Genetic profiling in acute myeloid leukaemia â”€ where are we and what is its role in patient management. British Journal of Haematology, 2013, 160, 303-320.	1.2	47
143	Is there a role for allogeneic transplantation in chronic myeloid leukemia?. Expert Review of Hematology, 2013, 6, 759-765.	1.0	7
144	Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood, 2013, 121, 339-350.	0.6	123

#	Article	IF	Citations
145	The myth of the second remission of acute leukemia in the adult. Blood, 2013, 121, 1077-1082.	0.6	192
146	Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood, 2013, 121, 4838-4841.	0.6	128
147	The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica, 2013, 98, 945-952.	1.7	54
148	Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib. Blood, 2013, 122, 3057-3057.	0.6	2
149	Early Bone Marrow Examination, On The Fifth Day Of Induction For AML, Is Highly Predictive Of Response. Blood, 2013, 122, 3893-3893.	0.6	1
150	Preemptive Detection Of JC Virus In Peripheral Blood Of Patients Undergoing Allogeneic Stem Cell Transplantation: A Potential Tool To Prevent Progressive Multifocal Leukoencephalopathy In High-Risk Patients?. Blood, 2013, 122, 4537-4537.	0.6	1
151	Interpreting Outcome Data in Hematological Malignancies: A Paradigm for Clinical Studies. Rambam Maimonides Medical Journal, 2013, 4, e0004.	0.4	1
152	Treatment for relapsed acute myeloid leukemia. Current Opinion in Hematology, 2012, 19, 89-94.	1.2	35
153	IGH@ Translocations, CRLF2 Deregulation, and Microdeletions in Adolescents and Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 3100-3108.	0.8	120
154	CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood, 2012, 120, 2297-2306.	0.6	92
155	How I treat hematologic emergencies in adults with acute leukemia. Blood, 2012, 120, 1993-2002.	0.6	57
156	The impact of mutational profiling on AML prognosis. Best Practice and Research in Clinical Haematology, 2012, 25, 403-408.	0.7	4
157	Total ambulatory hemato-oncological care: a myth or reality?. Leukemia and Lymphoma, 2012, 53, 2335-2336.	0.6	7
158	Hyperleukocytosis, leukostasis and leukapheresis: Practice management. Blood Reviews, 2012, 26, 117-122.	2.8	177
159	Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1079-1089.	13.9	1,688
160	Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability. Blood, 2012, 120, 603-612.	0.6	67
161	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: Risk stratified approach with a longâ€term followâ€up. American Journal of Hematology, 2012, 87, 875-879.	2.0	6
162	Outcomes in older adults with acute lymphoblastic leukaemia (<scp>ALL</scp>): results from the international <scp>MRC UKALL XII</scp>/<scp>ECOG</scp>2993 trial. British Journal of Haematology, 2012, 157, 463-471.	1.2	161

#	Article	IF	Citations
163	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation. Blood, 2012, 120, 578-578.	0.6	3
164	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. Blood, 2012, 120, 676-676.	0.6	2
165	Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 â€œEMERGEâ€•Study. Blood, 2012, 120, 905-905.	0.6	18
166	Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study. Blood, 2012, 120, 663-663.	0.6	0
167	Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. Blood, 2012, 120, 1875-1875.	0.6	0
168	Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 294-294.	0.6	0
169	Practically All Patients with Acute Myeloid Leukemia (AML) in Continuous Complete Remission for 3 Years or More Are Cured of Their Disease: The ECOG Experience. Blood, 2012, 120, 132-132.	0.6	0
170	Female Donor Allografts Have a Higher CD3 Content Than Male Donor Allografts: Potential Impact On Transplantation Outcomes in Male Recipients. Blood, 2012, 120, 587-587.	0.6	0
171	Prognostic Factors in Adult Acute Leukemia. Hematology/Oncology Clinics of North America, 2011, 25, 1163-1187.	0.9	11
172	Acute Leukemia. , 2011, , 235-250.		0
173	Interpreting Data on Transplant Selection and Outcome in Adult Acute Lymphoblastic Leukemia (ALL). Biology of Blood and Marrow Transplantation, 2011, 17, S76-S83.	2.0	13
174	Induction and postremission strategies in acute myeloid leukemia: what is new?. Current Opinion in Hematology, 2011, 18, 83-88.	1.2	14
175	Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood, 2011, 117, 5306-5313.	0.6	58
176	Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia. Trials, 2011, 12, 86.	0.7	7
177	Reply to induction therapy and outcome in acute myeloid leukemia. Cancer, 2011, 117, 2237-2237.	2.0	1
178	Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. Blood, 2011, 118, 258-258.	0.6	7
179	Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129. Blood, 2011, 118, 83-83.	0.6	5
180	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission. Blood, 2011, 118, 948-948.	0.6	3

#	Article	IF	Citations
181	Six Cycles of BEACOPP Tailored Based on Interim Scintigraphy Provide Favorable Outcome for Patients with Standard and Advanced Risk Hodgkin Lymphoma and Female Fertility Is Preserved: Results of a 10-Year Follow-up. Blood, 2011, 118, 1564-1564.	0.6	0
182	Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts. Blood, 2011, 118, 942-942.	0.6	0
183	Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,. Blood, 2011, 118, 3619-3619.	0.6	0
184	Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era. Blood, 2011, 118, 1576-1576.	0.6	0
185	Post-Engraftment Persistent Leukocytosis May Be An Independent Poor Prognostic Factor in Allogeneic Stem Cell Transplant Patients. Blood, 2011, 118, 4574-4574.	0.6	0
186	ETV6 Is An Early T-Cell Progenitor (ETP) Specific Tumor Suppressor Gene in Adult T-ALL. Blood, 2011, 118, 406-406.	0.6	1
187	Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. Current Opinion in Hematology, 2010, 17, 79-84.	1.2	9
188	Getting to the root of (it) ALL. Blood, 2010, 115, 3649-3650.	0.6	2
189	How I treat acute myeloid leukemia. Blood, 2010, 116, 3147-3156.	0.6	155
190	Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis. Cancer, 2010, 116, 5012-5021.	2.0	99
191	Prognostic factors in adult acute lymphoblastic leukaemia. British Journal of Haematology, 2010, 150, 389-405.	1.2	117
192	The evolving paradigm of prognostic factors in AML: Introduction to the Acute Leukemia Forum 2010. Best Practice and Research in Clinical Haematology, 2010, 23, 453-456.	0.7	3
193	Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood, 2010, 116, 4077-4085.	0.6	188
194	Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial. Blood, 2010, 116, 169-169.	0.6	13
195	BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation. Blood, 2010, 116, 2260-2260.	0.6	10
196	Maintenance Rituximab Every 2 Months for 2 Years Is Effective and Well Tolerated In Patients with Follicular Lymphoma with Both Standard or Rapid Infusion: Updated Results From the Phase IIIb MAXIMA Study. Blood, 2010, 116, 3945-3945.	0.6	2
197	Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial. Blood, 2010, 116, 493-493.	0.6	3
198	Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups. Blood, 2010, 116, 524-524.	0.6	6

#	Article	IF	Citations
199	High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. Blood, 2010, 116, 851-851.	0.6	4
200	A Population-Based Study In Acute Promyelocytic Leukemia (APL) Suggests a Higher Early Death Rate and Lower Overall Survival Than Commonly Reported In Clinical Trials: Data From the Surveillance, Epidemiology, and End Results (SEER) Program and the New York State Cancer Registry In the United States Between 1992â€“2007. Blood, 2010, 116, 872-872.	0.6	5
201	A Multi-Center Prospective Randomized Study Comparing Ibritumomab Tiuxetan (Zevalin) and High-Dose BEAM Chemotherapy (Z-BEAM) Vs. BEAM Alone as the Conditioning Regimen Prior to Autologous Stem-Cell Transplantation In Patients with Aggressive Lymphoma; Possible Advantage for Z-BEAM In Low-Risk Patients. Blood, 2010, 116, 686-686.	0.6	2
202	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 471-471.	0.6	0
203	Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997. Blood, 2010, 116, 924-924.	0.6	1
204	Single-Cell Phylogenetic analysis provides Novel Insight Into Resistance Mechanisms In AML. Blood, 2010, 116, 178-178.	0.6	0
205	Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902. Blood, 2010, 116, 3315-3315.	0.6	1
206	Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia. Blood, 2010, 116, 852-852.	0.6	5
207	Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. Blood, 2010, 116, 680-680.	0.6	0
208	Prognostic Implications of NOTCH1 and FBXW7 Mutations in Adults With T-Cell Acute Lymphoblastic Leukemia Treated on the MRC UKALLXII/ECOG E2993 Protocol. Journal of Clinical Oncology, 2009, 27, 4352-4356.	0.8	108
209	Optimal induction and post-remission therapy for AML in first remission. Hematology American Society of Hematology Education Program, 2009, 2009, 396-405.	0.9	77
210	Transplantation in adult ALL. Hematology American Society of Hematology Education Program, 2009, 2009, 593-601.	0.9	18
211	Anthracycline Dose Intensification in Acute Myeloid Leukemia. New England Journal of Medicine, 2009, 361, 1249-1259.	13.9	797
212	Optimal management of adults with ALL. British Journal of Haematology, 2009, 144, 468-483.	1.2	47
213	Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?. Best Practice and Research in Clinical Haematology, 2009, 22, 509-515.	0.7	3
214	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood, 2009, 114, 5136-5145.	0.6	346
215	Closer to the truth in AML. Blood, 2009, 113, 4129-4130.	0.6	8
216	Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia. Current Opinion in Hematology, 2009, 16, 453-459.	1.2	7

#	Article	IF	Citations
217	Prospective outcome data on 267 unselected adult patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood, 2009, 113, 4489-4496.	0.6	257
218	Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies â€“ A Curative Approach When Performed as a Primary Therapeutic Modality: A Single Center Experience.. Blood, 2009, 114, 1144-1144.	0.6	0
219	Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.. Blood, 2009, 114, 783-783.	0.6	2
220	Prior Response to Imatinib Predicts Response to Second Line Treatment with Nilotinib in CML Patients Resistant or Intolerant to Imatinib.. Blood, 2009, 114, 3297-3297.	0.6	0
221	Why is clinical progress in acute myelogenous leukemia so slow?. Best Practice and Research in Clinical Haematology, 2008, 21, 1-3.	0.7	9
222	Consolidation therapy: What should be the standard of care?. Best Practice and Research in Clinical Haematology, 2008, 21, 53-60.	0.7	12
223	Graft-versus-disease effect following allogeneic transplantation for acute leukaemia. Best Practice and Research in Clinical Haematology, 2008, 21, 485-502.	0.7	14
224	Clinical progress in acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2008, 21, 597-599.	0.7	1
225	Indications for Hematopoietic Cell Transplantation in Acute Leukemia. Biology of Blood and Marrow Transplantation, 2008, 14, 154-164.	2.0	7
226	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008, 111, 1827-1833.	0.6	702
227	Response: Chemotherapy or allografting for young adults with high-risk ALL?. Blood, 2008, 111, 5755-5755.	0.6	8
228	Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG). Blood, 2008, 112, 49-49.	0.6	4
229	Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma. Blood, 2008, 112, 826-826.	0.6	1
230	Induced CD4+CD25+ FOXP-3+ and CD8+CD25+ FOXP-3+t Cells Exhibit a Concurrent Expression of Effector and Selective Suppressive Capacities. Blood, 2008, 112, 3501-3501.	0.6	0
231	Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood, 2007, 109, 3189-3197.	0.6	655
232	Differential Gene Expression Patterns and Interaction Networks in BCR-ABLâ€“Positive and â€“Negative Adult Acute Lymphoblastic Leukemias. Journal of Clinical Oncology, 2007, 25, 1341-1349.	0.8	100
233	Recent Developments in Acute Myelogenous Leukemia Therapy. Oncologist, 2007, 12, 14-21.	1.9	21
234	Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood, 2007, 109, 944-950.	0.6	716

#	Article	IF	Citations
235	Closing the gap in CML. Blood, 2007, 109, 2271-2271.	0.6	1
236	How I treat acute lymphocytic leukemia in adults. Blood, 2007, 110, 2268-2275.	0.6	33
237	Alternative donor transplantation in acute myeloid leukemia: which source and when?. Current Opinion in Hematology, 2007, 14, 152-161.	1.2	24
238	Innovative Approaches in the Treatment and Support of Patients with Acute Myelogenous Leukemia. Oncologist, 2007, 12, 1-1.	1.9	89
239	Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.. Blood, 2007, 110, 1846-1846.	0.6	4
240	Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.. Blood, 2007, 110, 4381-4381.	0.6	1
241	Does Imatinib Change the Outcome in Philapdelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.. Blood, 2007, 110, 8-8.	0.6	22
242	Preface: significant advances in the biology and therapy of AML over the past four decades. Best Practice and Research in Clinical Haematology, 2006, 19, 259-262.	0.7	2
243	Is there a role for consolidation therapy pre-transplantation?. Best Practice and Research in Clinical Haematology, 2006, 19, 301-310.	0.7	4
244	Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood, 2006, 108, 88-96.	0.6	226
245	Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood, 2006, 108, 465-472.	0.6	205
246	In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).. Blood, 2006, 108, 2-2.	0.6	8
247	Allogeneic Stem Cell Transplantation (ASCT) in CML with Partial T-Cell Depletion, No Prophylaxis for Graft-Versus-Host Disease (GvHD) and Preemptive DLI for Patients with Post-Transplant Minimal Residual Disease (MRD): An Alternative Approach in CML Transplantation with Low Morbidity and Long Term Disease Free Survival.. Blood, 2006, 108, 318-318.	0.6	1
248	Expansion of Hematopoietic Stem Cells (HSC) from Cord-Blood (CB) Derived Mononuclear Cells (MNC) in Cytokine-Free Environment Using Mesenchymal Cells Spatial Co-Culture System.. Blood, 2006, 108, 2565-2565.	0.6	0
249	Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias.. Blood, 2006, 108, 1836-1836.	0.6	0
250	Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.. Blood, 2006, 108, 4589-4589.	0.6	0
251	Prognostic factors in acute myeloid leukemia. Current Opinion in Hematology, 2005, 12, 62-67.	1.2	33
252	Drug therapy for acute myeloid leukemia. Blood, 2005, 106, 1154-1163.	0.6	594

#	Article	IF	Citations
253	Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995). Leukemia and Lymphoma, 2005, 46, 55-61.	0.6	24
254	Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood, 2005, 106, 3760-3767.	0.6	595
255	Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.. Blood, 2005, 106, 546-546.	0.6	22
256	Outcomes of Unrelated Cord Blood and Haploidentical Stem Cell Transplantation in Adults with Acute Leukaemia.. Blood, 2005, 106, 301-301.	0.6	3
257	Use of Dendritic Cells Versus Peripheral Blood Lymphocytes To Segregate Alloreactive and Regulatory T Cells during Allogeneic Transplantation.. Blood, 2005, 106, 5244-5244.	0.6	0
258	Karyotype Is an Independent Prognostic Factor in Adult Acute Lymphoblastic Leukaemia (ALL): Analysis of Cytogenetic Data from 1,235 Patients on the Medical Research Council (MRC) UKALLXII /Eastern Cooperative Oncology Group (ECOG) 2993 Trial.. Blood, 2005, 106, 331-331.	0.6	1
259	Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome.. Blood, 2005, 106, 815-815.	0.6	0
260	Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).. Blood, 2005, 106, 894-894.	0.6	0
261	Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995). Journal of Clinical Oncology, 2004, 22, 1078-1086.	0.8	226
262	Acute Monocytic Leukemia (French-American-British classification M5) Does Not Have a Worse Prognosis Than Other Subtypes of Acute Myeloid Leukemia: A Report From the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2004, 22, 1276-1286.	0.8	66
263	State of the science for myelodysplastic syndrome: prognosis and promise of new therapies. Best Practice and Research in Clinical Haematology, 2004, 17, 535-541.	0.7	2
264	A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood, 2004, 103, 479-485.	0.6	260
265	State of the science for myelodysplastic syndrome: prognosis and promise of new therapies. Best Practice and Research in Clinical Haematology, 2004, 17, 535-541.	0.7	1
266	Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.. Blood, 2004, 104, 261-261.	0.6	5
267	CA-125 as a Marker for the Early Diagnosis of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation.. Blood, 2004, 104, 1138-1138.	0.6	0
268	Risk Factors for Outcomes of Family Haploidentical Allogeneic Stem Cell Transplantation for Adults with Acute Leukemias: A Survey on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2004, 104, 2146-2146.	0.6	0
269	Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and) Tj ETQq1 1 0.784314 rgBT /Ove 23-27.	2.0	10
270	Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. American Journal of Hematology, 2001, 66, 189-196.	2.0	34

#	Article	IF	Citations
271	Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: Before and after chemoprophylaxis and institution of HEPA filters. American Journal of Hematology, 2001, 66, 257-262.	2.0	210
272	Acute Myeloid Leukemia. Hematology American Society of Hematology Education Program, 2001, 2001, 62-86.	0.9	95
273	Concurrent use of growth factors and chemotherapy in acute leukemia. Current Opinion in Hematology, 2000, 7, 197-202.	1.2	8
274	Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 2000, 96, 4075-4083.	0.6	1,442
275	Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. New England Journal of Medicine, 1998, 339, 1649-1656.	13.9	569
276	All-trans-Retinoic Acid in Acute Promyelocytic Leukemia. New England Journal of Medicine, 1997, 337, 1021-1028.	13.9	1,006
277	Intensifying Induction Therapy in Acute Myeloid Leukemia: Has a New Standard of Care Emerged?. Blood, 1997, 90, 2121-2126.	0.6	47
278	Effects of GM-CSF on Ki67 expression and cell cycle traverse in acute myelogenous leukemia specimens and cell lines. Leukemia Research, 1994, 18, 609-616.	0.4	8